Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.

Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-(3-methoxy-4-4-(4-methylpiperazin-1-yl)piperidin-1-yl phenylamino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.

Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.

Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides compositions and methods of their use in treating muscular dystrophy and other disorders.

Abstract: A use of Magnolia figo extract in the manufacture of a compound for inhibiting growth of lung cancer cells.

Abstract: A compound 2-(1-(2-hydroxypropyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridine compound, its synthesis, and its use as an anticancer agent.

Abstract: A method for preventing or treating a tissue injury and/or promoting tissue repair in a subject in need thereof, includes administering to the subject a therapeutically effective amount of an ADH inhibitor, AKR inhibitor, SCoR inhibitor, and/or PKM2 inhibitor.

Abstract: The invention relates to a composition in the form of an oil-in-water emulsion, in particular a cosmetic and/or dermatological composition, comprising in a physiologically acceptable aqueous medium: a) at least Baicalin and/or one of the derivatives thereof or a plant extract containing it, b) at least one superabsorbent polymer, c) at least one homo- or copolymer of non-superabsorbent acrylic acid that is at least partially neutralized, and d) at least one gemini surfactant with formula (III), said composition having a p H of 6.0 to 6.5. The invention also relates to a cosmetic care and/or makeup method for keratin materials, comprising the topical application of a composition according to the invention on keratin materials.

Abstract: The present invention provides a method for treatment or prevention of cancer through novel action mechanism, namely, through inhibition of a riboflavin pathway. The method for treatment or prevention of cancer comprises administering an RF pathway inhibitor to a subject in need thereof.

Abstract: An 4,5-bis(4-chlorophenyl)-1-hexyl-2-(3,4-dimethoxyphenyl)-1H-imidazole compound, its synthesis, and its use as an antimicrobial agent.

Abstract: A 6?-(3-bromophenyl)-2?-methoxy-3,4?-bipyridine-3?-carbonitrile as antioxidant compound, its synthesis, and its use as an antioxidant agent.

Abstract: A 4-(4-bromophenyl)-2-alkyloxy-6-(2-oxo-2H-1-benzopyran-3-yl)pyridine-3-carbonitrile compound, its synthesis, and its use as an antimicrobial agent.

Abstract: A 6?-(4-bromophenyl)-2?-ethoxy-3,4?-bipyridine-3?-carbonitrile compound, its synthesis, and its use as an antimicrobial agent.

Abstract: A 6?-(2-bromophenyl)-2?-ethoxy-3,4?-bipyridine-3?-carbonitrile as antioxidant compound, its synthesis, and its use as an antioxidant agent.

Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

Abstract: Methods of reducing the viability of cancer cells, preventing cancer cells of a subject from developing resistance to TTFields, and restoring sensitivity of cancer cells to TTFields by recommending or prescribing a PTGER3 inhibitor to a subject and applying an alternating electric field to the cancer cells are provided. In some instances, sensitivity of cancer cells to TTFields can be restored with one or more PTGER3 inhibitors (e.g., NSAIDs, cox2 inhibitors).

Abstract: Various embodiments relate to compounds and methods useful for preventing or treating a cancer in a subject. The method may include administering to a subject a composition according to any of the embodiments described herein in an amount effective to inhibit metastatic activity or tumor growth in the subject.

Abstract: Novel 5-substituted aminopyrimido[6?,1?:2,3]imidazo[4,5-c][1,6]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The 5-substituted aminopyrimido[6?,1?:2,3]imidazo[4,5-c][1,6]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

Abstract: Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts selected from sodium, potassium, calcium, and magnesium salts. The BHB composition may also include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, one or more ketone precursors, supplements, or other compounds that cause a rise in blood ketone levels without adding more electrolytes to the bloodstream, a short-, medium-, or long-chain fatty acid source, vitamins, minerals, flavorants, or other excipients.